{"id":52800,"date":"2023-01-11T15:02:14","date_gmt":"2023-01-11T14:02:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/"},"modified":"2023-01-11T15:02:14","modified_gmt":"2023-01-11T14:02:14","slug":"dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/","title":{"rendered":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138"},"content":{"rendered":"
\n

OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR)<\/a>, an early phase CRO specializing in Phase I trials, announced that it has administered the first dose of Aclaris Therapeutics\u2019 ATI-2138 in a Phase I multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase I MAD study in healthy volunteers is being conducted at DVCR\u2019s world-class clinical pharmacology unit.\n<\/p>\n

<\/a><\/p>\n

\nThe study will enroll 60 participants across five cohorts. Many features of the facility were engineered specifically with the conduct of ascending dose trials in mind, including dedicated vital signs machines at every bedside to enhance data quality for dose escalation meetings and luxurious amenities to improve participant retention throughout the entire duration of the trial.\n<\/p>\n

\nDVCR\u2019s George Atiee, M.D<\/a>., is serving as the principal investigator on the trial. \u201cI am honored and excited to be a part of this trial in ATI-2138\u2019s development. Fortunately, the research campus has been purpose-built to further empower our operations team to deliver on our commitments,\u201d said Dr. Atiee.\n<\/p>\n

\nDr. Vince Clinical Research looks forward to the successful completion of this trial and delivering on its promise to provide Smarter, Faster Data to its biopharmaceutical sponsors.\n<\/p>\n

\nAbout Dr. Vince Clinical Research<\/b>\n<\/p>\n

\nDr. Vince Clinical Research (DVCR)<\/a> is a world-class CRO (Contract Research Organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR\u2019s complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP compliant pharmacy with positive and negative pressure compounding rooms. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. By leveraging both technology and one of the country\u2019s most experienced leadership teams, DVCR provides Smarter, Faster Data to their biopharmaceutical clients.\n<\/p>\n

\nWebsite: https:\/\/sponsors.drvince.com<\/a>\n<\/p>\n

\nLinkedIn: https:\/\/www.linkedin.com\/company\/dr-vince-clinical-research\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nZach Bader
\n
Vice President, Business Development
\n
913-333-3000
\n
zbader@drvince.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase I trials, announced that it has administered the first dose of Aclaris Therapeutics\u2019 ATI-2138 in a Phase I multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase I MAD … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52800","6":"format-standard","7":"category-industry"},"yoast_head":"\nDr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase I trials, announced that it has administered the first dose of Aclaris Therapeutics\u2019 ATI-2138 in a Phase I multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase I MAD ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-11T14:02:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138\",\"datePublished\":\"2023-01-11T14:02:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/\"},\"wordCount\":352,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005175\\\/en\\\/1682511\\\/21\\\/DrVince_Logo_RGB_600px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/\",\"name\":\"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005175\\\/en\\\/1682511\\\/21\\\/DrVince_Logo_RGB_600px.jpg\",\"datePublished\":\"2023-01-11T14:02:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005175\\\/en\\\/1682511\\\/21\\\/DrVince_Logo_RGB_600px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005175\\\/en\\\/1682511\\\/21\\\/DrVince_Logo_RGB_600px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend","og_description":"OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase I trials, announced that it has administered the first dose of Aclaris Therapeutics\u2019 ATI-2138 in a Phase I multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase I MAD ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-11T14:02:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138","datePublished":"2023-01-11T14:02:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/"},"wordCount":352,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/","url":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/","name":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg","datePublished":"2023-01-11T14:02:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230111005175\/en\/1682511\/21\/DrVince_Logo_RGB_600px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dr-vince-clinical-research-announces-dosing-of-aclaris-therapeutics-phase-i-mad-study-of-ati-2138\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52800"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52800\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}